Biotechnology
Mycrodose Therapeutics Receives US DEA Schedule I License to Research Four (4) Psychedelic Compounds
Excerpt from the Press Release: Mycrodose Therapeutics is pleased to announce that the company has been approved by the United States Drug Enforcement Agency (DEA), State of California Attorney General’s Research Advisory Board, and The US Food & Drug Administration (FDA) to research four (4) psychedelic compounds at their San Diego, California laboratory. The company’s Schedule…
Read More
Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Aug. 23, 2021 (GLOBE NEWSWIRE) — NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today disclosed its fourth oncology development candidate, NGM831, an antagonist antibody designed to block the interaction of ILT3 with fibronectin, as well…
Read More
Excerpt from the Press Release: LEXINGTON, Mass., Aug. 26, 2021 (GLOBE NEWSWIRE) — Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that results from a global Phase 2 clinical study of balstilimab monotherapy in…
Read More
Excerpt from the Press Release: BALTIMORE and PALO ALTO, Calif., Aug. 20, 2021 /PRNewswire/ — A novel machine learning based blood testing technology that could help to increase detection of early-stage lung cancer demonstrated promising results in a study published in Nature Communications1. Delfi Diagnostics Inc.’s lung cancer screening technology, which uses advanced machine learning algorithms to analyze genome-wide cell-free DNA…
Read More
Excerpt from the Press Release: SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today highlighted positive interim clinical data from the Company’s FT516 and FT596 programs for patients with relapsed / refractory B-cell lymphoma. FT516 is the Company’s universal, off-the-shelf…
Read More
Excerpt from the Press Release: Immunization with a protein-based immunogen, DYAI-100, a receptor binding domain (RBD) of SARS-CoV-2, resulted in potent B cell immunity in preclinical studies, with strong serological recognition of the original SARS-CoV-2 virus and major variants of concern (Alpha, Beta, Gamma, and Delta; “VOCs”). The sera of vaccinated mice demonstrated potent neutralization…
Read More
Excerpt from the Press Release: Since the early days of the COVID pandemic, scientists have aggressively pursued the secrets of the mechanisms that allow severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to enter and infect healthy human cells. Early in the pandemic, University of California San Diego’s Rommie Amaro, a computational biophysical chemist, helped develop…
Read More
Excerpt from the Press Release: PEABODY, Mass., Aug. 19, 2021 /PRNewswire/ — Privo Technologies, Inc. (“Privo”), a biopharmaceutical company focused on breakthrough localized treatments for tough to treat mucosal cancers, announced today that Privo and its CEO, Manijeh Goldberg, Ph.D., have been selected as the winner of the AIM-HI Accelerator Fund’s Inaugural Women’s Venture Competition. Privo was selected from…
Read More
Excerpt from the Press Release: SAN FRANCISCO, CA / ACCESSWIRE / August 19, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) With much anticipation, Oncology Pharma, Inc. has finalized a Co-Development Agreement with NanoSmart Pharmaceuticals, Inc. Oncology Pharma will pursue the early feasibility and nonclinical development of a dactinomycin nanoemulsion drug product intended for the treatment of…
Read More
Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Aug. 19, 2021– Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays and services, today announced that new data show the company’s cerebrospinal fluid assay, CNSide™, detected tumor cells and identified actionable mutations in lung cancer patients with leptomeningeal carcinomatosis, allowing for targeted treatment decisions that may improve outcomes…
Read More